MedTrace Logo

Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

NCT05960955 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2023-11-18

No results posted yet for this study

Summary

This trial is a Phase II study. All patients are resectable Gastric or Gastroesophageal Junction Adenocarcinoma, Eastern Cooperative Oncology Group (ECOG) performance status 0-1.The purpose of this study is to evaluate the efficacy and safety of cadonilimab combined with chemotherapy with or without AK117 neoadjuvantin treatment of resectable Gastric or Gastroesophageal Junction Adenocarcinoma.

Conditions

  • Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

Cadonilimab

IV infusion,Specified dose on specified days

DRUG

AK117

IV infusion,Specified dose on specified days

DRUG

Oxaliplatin

IV infusion,Specified dose on specified days

DRUG

Tegafur-gimeracil-oteracil potassium

Oral,Specified dose on specified days

DRUG

Docetaxel

IV infusion,Specified dose on specified days

DRUG

5-Fluorouracil

IV infusion,Specified dose on specified days

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-13
Primary Completion
2024-11-30
Completion
2027-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05960955 on ClinicalTrials.gov